{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:24:33Z","timestamp":1762917873577,"version":"3.40.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.anndiagpath.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T17:29:51Z","timestamp":1522862991000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-7152","authenticated-orcid":false,"given":"Prerna","family":"Guleria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuzhat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9942-3403","authenticated-orcid":false,"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajinder","family":"Parshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepali","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.anndiagpath.2018.03.012_bb0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11864-017-0495-8","article-title":"Novel agents in the treatment of Thymic malignancies","volume":"18","author":"du Vignaux","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2018.03.012_bb0010","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.21037\/jtd.2016.05.66","article-title":"Non-surgical treatment of locally advanced thymic epithelial tumors\u2014a need for multicenter trials","volume":"8","author":"Roden","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/CMAR.S57550","article-title":"New modalities of cancer treatment for NSCLC: focus on immunotherapy","volume":"6","author":"Davies","year":"2014","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0020","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"5","key":"10.1016\/j.anndiagpath.2018.03.012_bb0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5306\/wjco.v6.i5.96","article-title":"New findings on thymic epithelial tumors: something is changing","volume":"6","author":"Berardi","year":"2015","journal-title":"World J Clin Oncol"},{"year":"2015","series-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","key":"10.1016\/j.anndiagpath.2018.03.012_bb0030"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0035","series-title":"IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer. 1st ed","first-page":"73","article-title":"PD-L1 SP263 assay","author":"Dacic","year":"2015"},{"issue":"3","key":"10.1016\/j.anndiagpath.2018.03.012_bb0040","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.anndiagpath.2018.03.012_bb0045","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/JTO.0b013e31821e7b12","article-title":"A review of prognostic factors in thymic malignancies","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2018.03.012_bb0050","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2018.03.012_bb0055","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","article-title":"Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy","volume":"99","author":"Katsuya","year":"2016","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.anndiagpath.2018.03.012_bb0065","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12253-016-0144-8","article-title":"Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets","volume":"23","author":"Enkner","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","article-title":"PD-L1, PD-1, CD4, and CD8 expression in neoplastic and non neoplastic thymus","volume":"60","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2018.03.012_bb0080","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2018.03.012_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182665","article-title":"Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors","volume":"12","author":"Arbour","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.anndiagpath.2018.03.012_bb0090","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.anndiagpath.2018.03.012_bb0095","article-title":"Solid tumor clinical trials evaluating use of avelumab","volume":"39","author":"Simoneaux","year":"2017","journal-title":"Oncol Times"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13000-016-0494-2","article-title":"Quantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3N","volume":"11","author":"Smith","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.anndiagpath.2017.07.001","article-title":"Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: a report from India","volume":"31","author":"Vallonthaiel","year":"2017","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2018.03.012_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"26","key":"10.1016\/j.anndiagpath.2018.03.012_bb0115","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.anndiagpath.2018.03.012_bb0120","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.124","article-title":"Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers","volume":"112","author":"Moreno","year":"2015","journal-title":"Br J Cancer"},{"issue":"7528","key":"10.1016\/j.anndiagpath.2018.03.012_bb0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.anndiagpath.2018.03.012_bb0130","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","article-title":"Durable Cancer regression off-treatment and effective re-induction therapy with an anti-PD-1 antibody","volume":"19","author":"Lipson","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6230","key":"10.1016\/j.anndiagpath.2018.03.012_bb0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"7528","key":"10.1016\/j.anndiagpath.2018.03.012_bb0140","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.anndiagpath.2018.03.012_bb0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cllc.2015.03.008","article-title":"Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non\u2013small-cell lung cancer","volume":"16","author":"Kitazono","year":"2015","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.anndiagpath.2018.03.012_bb0150","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.anndiagpath.2018.03.012_bb0155","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2018.03.012_bb0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/intimm\/dxu095","article-title":"Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies","volume":"27","author":"Philips","year":"2014","journal-title":"Int Immunol"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0165","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.anndiagpath.2018.03.012_bb0170","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2018.03.012_bb0175","first-page":"119","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis","volume":"78","author":"Maeda","year":"2016","journal-title":"Nagoya J Med Sci"},{"issue":"1","key":"10.1016\/j.anndiagpath.2018.03.012_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.anndiagpath.2018.03.012_bb0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JND-170219","article-title":"Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy","volume":"4","author":"Cooper","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anndiagpath.2018.03.012_bb0195","first-page":"1","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","author":"Chen","year":"2017","journal-title":"Clin Toxicol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913418300133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913418300133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T02:18:12Z","timestamp":1604110692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913418300133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":39,"alternative-id":["S1092913418300133"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2018.03.012","relation":{},"ISSN":["1092-9134"],"issn-type":[{"type":"print","value":"1092-9134"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}